Pfizer shares zoom nearly 9% after marketing and supply agreement with Mylan Pharmaceuticals
Pfizer shares surged 8.6% to Rs 4,448.35 after announcing a marketing and supply agreement with Mylan Pharmaceuticals for Ativan and Pacitane. The five-year deal aims to enhance distribution and ...
Mylan's Copaxone Suit Against Teva Should Survive, Judge Says
Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...
pharmaphorum7y
Mylan debuts generic Seretide in UK
Mylan has become the first company to launch a generic version of GlaxoSmithKline's (GSK) big-selling respiratory drug Seretide in the UK. Seretide (salmeterol xinafoate/fluticasone propionate ...
Pfizer shares rise by 7% after marketing and sale pact with Mylan for two neuro therapy brands
The marketing and supply agreement is for a period of five years for India only, to enhance distribution and in clinic presence of the two products.
Pfizer partners with Mylan for Marketing of Ativan and Pacitane
Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.
NDTV Profit17d
Pfizer Share Price Jumps After Pact With Mylan Pharmaceuticals
Shares of Pfizer Ltd. rose over 8% on Monday after the company signed a sales and marketing pact with Mylan Pharmaceuticals Pvt. The contract is for two brands of the company.